|Day Low/High||3.70 / 4.00|
|52 Wk Low/High||2.50 / 14.84|
Anavex (AVXL) announced on Thursday its Anavex 2-73 Parkinson's treatment was successful in a preclinical study.
Michael J. Fox Foundation funded ANAVEX 2-73 drug candidate study presented at World Parkinson Congress 2016
Conference to Feature Companies with Focus on Alzheimer's, Parkinson's and other Neurological Diseases
Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Anavex Life Sciences Corp , where a total volume of 10,707 contracts has been traded thus far today, a contract volume which is representative of approximately 1.1 million underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 90.4% of AVXL's average daily trading volume over the past month, of 1.2 million shares.
A small group of Alzheimer's patients treated with Anavex 2-73 are exhibiting signs of memory loss, faltering cognition and inability to take care of themselves over time.
Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Anavex Life Sciences Corp , where a total of 3,227 contracts have traded so far, representing approximately 322,700 underlying shares. That amounts to about 41.6% of AVXL's average daily trading volume over the past month of 776,365 shares.
These stocks look ready to break out and trade higher from current levels.
Shared clinical phenotypes and underlying pathophysiology of Autism-Related Disorders such as Fragile X and Rett syndrome, indicates that ANAVEX 2-73 could be of interest to investigate clinically in these disorders
Detailed Data to be Presented at Upcoming Scientific Meeting
Too many investors have a fundamental misunderstanding about the significance of orphan drug designation. I should say, insignificance, because the FDA delineation, on its own, means very little.
Stocks edge higher on Friday afternoon as crude oil continues to race toward the $40 level.
Stocks extend highs on Friday as a surge in crude oil boosts the energy sector.
Anavex (AVXL) stock is surging in mid-morning trading on Friday after the FDA granted the company's dementia treatment with an Orphan Drug Designation.
Stock futures set up for a bounce on Friday in a hard left turn to the selloff that punished Wall Street a day earlier.
Results Demonstrate Significant Reversal in Cognitive Deficit, Inflammation and Alzheimer's-like Amyloid Pathology
Trial Extension Granted at Request of Patients and Caregivers